Усовершенствование и оптимизация терапевтических аналогов инфликсимаба ‒ антитела против TNFα
Молекулярная биология · 2018
DOI: 10.1134/s0026898418040183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Молекулярная биология, 2018. Verfasst von X-J Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: International Joint Cancer Institute, Second Military Medical University, Shanghai, 200433 People's Republic of China.
Abstract (Originalsprache)
Previously, we have reported the crystal structures of Fab fragment of Infliximab in complex with TNFα. The structurally identified epitope on TNFα revealed the mechanism of TNFα inhibition by partially overlapping with the TNFα-receptor interface and the possibility to optimize the binding affinity. In this study, we launched a screen of a phage display library to isolate novel anti-TNFα antibodies based on the infliximab epitope. To develop novel anti-TNFα antibodies, structural analysis, the phage display antibody isolation, step by step antibody optimization, CDR residues random mutagenesis, and binding affinity characterization were performed. One of the novel antibodies generated on the backbone of infliximab, Inf3D6, has the superior binding affinity to TNFα, thus, demonstrating the potential for structure guided optimization for improvement of existing antibody-based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Joint Cancer Institute, Second Military Medical University, Shanghai, 200433 People's Republic of China.
- Central Laboratory, Navy General Hospital of PLA, Beijing, 100048 People's Republic of China.
- Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, 200433 People's Republic of China.
- Department of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai, 200433 People's Republic of China.
- Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318 People's Republic of China.
- hus@smmu.edu.cn.
Zitieren
APA
Yu, X. J., Shen, Y. F., Dong, J., Li, T., Wang, C., Zhang, Y. J., Wang, L. F., Meng, Y. C., Yang, Y., Wang, H. J., Lei, C. H., Hu, S., & Li, B. H. (2018). Усовершенствование и оптимизация терапевтических аналогов инфликсимаба ‒ антитела против TNFα. Молекулярная биология. https://doi.org/10.1134/s0026898418040183
Vancouver
Yu XJ, Shen YF, Dong J, Li T, Wang C, Zhang YJ, et al. Усовершенствование и оптимизация терапевтических аналогов инфликсимаба ‒ антитела против TNFα. Молекулярная биология. 2018. doi:10.1134/s0026898418040183
BibTeX
@article{Yu2018,
author = {Yu, X-J and Shen, Y-F and Dong, J and Li, T and Wang, C and Zhang, Y-J and Wang, L-F and Meng, Y-C and Yang, Y and Wang, H-J and Lei, C-H and Hu, S and Li, B-H},
title = {Усовершенствование и оптимизация терапевтических аналогов инфликсимаба ‒ антитела против TNFα},
journal = {Молекулярная биология},
year = {2018},
doi = {10.1134/s0026898418040183}
}
EUVIMED